Rxivist logo

Proteome-wide analysis of differentially-expressed SARS-CoV-2 antibodies in early COVID-19 infection

By Xiaomei Zhang, Xian Wu, Dan Wang, Minya Lu, Xin Hou, Hongye Wang, Te Liang, Jiayu Dai, Hu Duan, Yingchun Xu, Yongzhe Li, Xiaobo Yu

Posted 20 Apr 2020
medRxiv DOI: 10.1101/2020.04.14.20064535

Rapid and accurate tests that detect IgM and IgG antibodies to SARS-CoV-2 proteins are essential in slowing the spread of COVID-19 by identifying patients who are infected with COVID-19. Using a SARS-CoV-2 proteome microarray developed in our lab, we comprehensively profiled both IgM and IgG antibodies in forty patients with early-stage COVID-19, influenza, or non-influenza who had similar symptoms. The results revealed that the SARS-CoV-2 N protein is not an ideal biomarker for COVID-19 diagnosis because of its low immunogenicity, thus tests that rely on this marker alone will have a high false negative rate. Our data further suggest that the S protein subunit 1 receptor binding domain (S1-RBD) might be the optimal antigen for IgM antibody detection, while the S protein extracellular domain (S1+S2ECD) would be the optimal antigen for both IgM and IgG antibody detection. Notably, the combination of all IgM and IgG biomarkers can identify 87% and 73.3% COVID-19 patients, respectively. Finally, the COVID-19-specific antibodies are significantly correlated with the clinical indices of viral infection and acute myocardial injury (p[≤]0.05). Our data may help understand the function of anti-SARS-CoV-2 antibodies and improve serology tests for rapid COVID-19 screening.

Download data

  • Downloaded 2,423 times
  • Download rankings, all-time:
    • Site-wide: 7,138
    • In infectious diseases: 1,166
  • Year to date:
    • Site-wide: 32,384
  • Since beginning of last month:
    • Site-wide: 49,545

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide